Healthcare · Biotechnology
Price
$2.83
Market Cap
$202.5M
Employees
108
Beta
0.90
Avg Volume
753,085
CEO
Paul J. Hastings
Business Description
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Business History
Price Overview
Last updated: Jun 27, 2026 9:03am (just now)$2.83
+0.05 (+1.80%)
Day Range
$2.68 – $2.90
52-Week Range
$1.63 – $3.65
50-Day MA
$2.92
200-Day MA
$2.32
Volume
1,217,828.00
Analyst Price Targets
Low
$9.00
Consensus
$9.00
High
$9.00
(7 analysts)
Share Structure
Outstanding
71,545,358.00
Float
54,303,387.00
Free Float
75.9%
Normal free float
— 75.9% of shares trade freely, ~24.1% held by insiders/institutions
Healthy float typical of established companies. Good liquidity for entering and exiting positions without major price impact.
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
CALCStock Price / EPS (Diluted)
-2.01
Stock Price: $2.83
EPS (Diluted): -1.41
EPS (Diluted): -1.41
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
0.44
Stock Price: $2.83
Total Equity: $312.33M
Shares: 73,991,197
Total Equity: $312.33M
Shares: 73,991,197
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
-2.76
Market Cap: $202.47M
Total Debt: $0.00
Cash: $39.63M
EBITDA: -$94.89M
Total Debt: $0.00
Cash: $39.63M
EBITDA: -$94.89M
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
$173.7M
Market Cap: $202.47M
Total Debt: $0.00
Cash: $39.63M
Total Debt: $0.00
Cash: $39.63M
P/S Ratio (Price per dollar of revenue)
APIStock Price / Revenue Per Share
0.00
Stock Price: $2.83
Revenue: $0.00
Shares: 73,991,197
Revenue: $0.00
Shares: 73,991,197
EV/Sales (Total value vs revenue — works when P/E can't)
API0.00
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
0.0%
Gross Profit: -$9.19M
Revenue: $0.00
Revenue: $0.00
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
0.0%
Operating Income: -$121.21M
Revenue: $0.00
Revenue: $0.00
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
0.0%
Net Income: -$104.08M
Revenue: $0.00
Revenue: $0.00
ROE (Profit from shareholder equity)
APINet Income / Total Equity
-30.9%
Net Income: -$104.08M
Total Equity: $312.33M
Total Equity: $312.33M
ROIC (Profit from all invested capital)
APINOPAT / Invested Capital
-32.2%
Operating Income: -$121.21M
Tax Rate: 0.0%
Equity: $312.33M
Total Debt: $0.00
Cash: $39.63M
Tax Rate: 0.0%
Equity: $312.33M
Total Debt: $0.00
Cash: $39.63M
Zero debt — invested capital = equity minus cash (very efficient)
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
12.69
Current Assets: $282.51M
Current Liabilities: $22.27M
Current Liabilities: $22.27M
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
0.00
Short-Term Debt: $0.00
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: $312.33M
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: $312.33M
Zero debt — this company carries no debt obligations. Strongest possible score.
Rev/Share (Top-line per share)
Revenue / Shares Outstanding
—
Revenue: $0.00
Shares: 73,991,197
Shares: 73,991,197
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$4.22
Total Equity: $312.33M
Shares: 73,991,197
Shares: 73,991,197
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$-1.22
Operating CF: -$88.70M
CapEx: -$1.21M
Shares: 73,991,197
CapEx: -$1.21M
Shares: 73,991,197
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $2.83
Stock Price: $2.83
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$104.08M
Net Income: -$104.08M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares NKTX against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Last updated: Jun 21, 2026 7:16pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Cost of Revenue | $0 | $0 | $5.9M | $0 | $9.2M |
| Gross Profit | $0 | $0 | -$5.9M | $0 | -$9.2M |
| Operating Expenses | $86.4M | $119.0M | $125.8M | $128.2M | $112.0M |
| Operating Income | -$86.4M | -$119.0M | -$131.7M | -$128.2M | -$121.2M |
| Net Income | -$86.1M | -$113.8M | -$117.5M | -$108.8M | -$104.1M |
| EBITDA | -$84.3M | -$105.6M | -$120.5M | -$99.6M | -$94.9M |
| EPS | $-2.62 | $-2.61 | $-2.40 | $-1.60 | $-1.41 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 21, 2026 7:16pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $60.8M | $37.5M | $31.0M | $27.9M | $39.6M |
| Total Current Assets | $245.8M | $360.7M | $253.1M | $273.3M | $282.5M |
| Total Assets | $273.9M | $472.9M | $378.9M | $501.2M | $404.2M |
| Current Liabilities | $12.9M | $22.0M | $23.3M | $18.9M | $22.3M |
| Long-Term Debt | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $22.9M | $100.7M | $105.6M | $93.2M | $91.9M |
| Total Equity | $251.0M | $372.2M | $273.3M | $408.0M | $312.3M |
| Retained Earnings | -$204.1M | -$317.9M | -$435.4M | -$544.2M | -$648.3M |
Cash Flow (Annual)
Last updated: Jun 21, 2026 7:16pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$67.9M | -$57.0M | -$86.2M | -$99.7M | -$88.7M |
| Capital Expenditure | -$5.0M | -$47.1M | -$28.1M | -$4.4M | -$1.2M |
| Free Cash Flow | -$73.0M | -$104.1M | -$114.3M | -$104.1M | -$89.9M |
| Acquisitions (net) | $-37,559 | $137,578 | $0 | $0 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | -$34.2M | -$22.7M | -$6.5M | -$3.2M | $11.8M |
Analyst Estimates (Annual)
Last updated: Jun 27, 2026 9:03am (just now)| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue |
$6.5M $6.5M – $6.5M
|
$4.3M $4.3M – $4.3M
|
$85.7M $85.7M – $85.7M
|
$107.4M $107.4M – $107.4M
|
| EBITDA | $0 | $0 | $0 | $0 |
| Net Income |
-$128.2M -$155.9M – -$41.6M
|
-$89.3M -$95.5M – -$83.0M
|
-$59.0M -$59.0M – -$59.0M
|
-$55.6M -$55.6M – -$55.6M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 21, 2026 7:16pm (5d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | — | — | — | — |
| Gross Profit Growth | — | — | +100.0% | — |
| Operating Income Growth | -37.6% | -10.7% | +2.6% | +5.5% |
| Net Income Growth | -32.3% | -3.2% | +7.4% | +4.3% |
| EBITDA Growth | -25.3% | -14.1% | +17.3% | +4.8% |
Insider Trading (Recent)
Type codes
PPurchase
SSale
AAward / grant
MOption exercise
FIn-kind (tax)
CConversion
GGift
DReturn to issuer
All SEC Form 4 codes
Open market
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
Compensation (Rule 16b-3)
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
Derivatives
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
Other exempt
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
Other
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-06-18 | HASTINGS PAUL J | S-Sale | 1,776.00 | $2.71 | $4,813 |
| 2026-06-10 | RA CAPITAL MANAGEMENT, L.P. | A-Award | 37,000.00 | $2.46 | $91,020 |
| 2026-06-10 | Behbahani Ali | A-Award | 37,000.00 | $2.46 | $91,020 |
| 2026-06-10 | George Simeon | A-Award | 37,000.00 | $2.46 | $91,020 |
| 2026-06-10 | Vratsanos George | A-Award | 37,000.00 | $2.46 | $91,020 |
| 2026-06-10 | Scheiner Zachary | A-Award | 37,000.00 | $2.46 | $91,020 |
| 2026-06-10 | PATTERSON LEONE D | A-Award | 37,000.00 | $2.46 | $91,020 |
| 2026-06-10 | Dybbs Michael | A-Award | 37,000.00 | $2.46 | $91,020 |
| 2026-06-10 | Thedinga Angela | A-Award | 37,000.00 | $2.46 | $91,020 |
| 2026-01-15 | HASTINGS PAUL J | S-Sale | 26,046.00 | $2.07 | $53,915 |
| 2026-01-15 | Mahmood Nadir | S-Sale | 5,649.00 | $2.07 | $11,693 |
| 2026-01-06 | Rose Shawn Marshall | A-Award | 139,000.00 | $1.93 | $268,270 |
| 2026-01-06 | Rose Shawn Marshall | A-Award | 70,000.00 | $0.00 | $0 |
| 2026-01-06 | Mahmood Nadir | A-Award | 80,000.00 | $0.00 | $0 |
| 2026-01-06 | Mahmood Nadir | A-Award | 160,000.00 | $1.93 | $308,800 |
| 2026-01-06 | HASTINGS PAUL J | A-Award | 562,000.00 | $1.93 | $1.1M |
| 2026-01-06 | HASTINGS PAUL J | A-Award | 94,000.00 | $0.00 | $0 |
| 2025-06-23 | Rose Shawn Marshall | A-Award | 500,000.00 | $1.75 | $875,000 |
| 2025-06-23 | Rose Shawn Marshall | 0.00 | $0.00 | $0 | |
| 2025-06-18 | HASTINGS PAUL J | S-Sale | 1,790.00 | $1.79 | $3,204 |
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for NKTX — it's generated by the pipeline (
market-narrative step).
No community reviews yet for NKTX.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.352 · d1100787 · 2026-06-26 11:39:30